Event driven move in Revolution Medicines stock

Revolution Medicines (RVMD) is back in focus after positive Phase III results for its lead drug, Daraxonrasib, in metastatic pancreatic cancer and new FDA designations that could streamline the regulatory timeline.

The FDA granted Daraxonrasib both Breakthrough Therapy and Orphan Drug status, and the company is preparing a New Drug Application while advancing several late stage trials, developments investors are watching closely.

At a share price of $186.16, Revolution Medicines has seen a 14.22% 1 month share price return and a 27.31% 3 month share price return, while the 1 year total shareholder return is very large, reflecting how the Phase III data and FDA designations have shifted expectations around growth prospects and risk.

If you are looking for other potential oncology and drug discovery stories that could be shaped by data and regulation, it may be worth scanning 39 healthcare AI stocks

After Revolution Medicines' sharp move and with the stock trading below both analyst targets and some intrinsic value estimates, is the discount a sign of market caution that still makes sense, or a mispricing following the trial win?

Most Popular Narrative: 39.2% Overvalued

Compared with the most followed fair value estimate of $133.70, Revolution Medicines at $186.16 reflects a much higher price than that narrative implies. This puts the underlying growth and margin assumptions firmly in focus.

The move toward targeted oncology treatments for high unmet need tumors such as pancreatic, lung and colorectal cancer aligns with the company’s RAS(ON) portfolio, which could influence long term revenue growth if multiple registrational programs convert to approved therapies.

Curious what kind of revenue ramp, margin lift and future earnings multiple are built into that fair value? The narrative leans on aggressive top line expansion, margin normalization and a rich future profit multiple that rivals fast growing sectors. Want to see how those moving parts fit together and what has to go right for the story to hold?

Result: Fair Value of $133.70 (OVERVALUED)

However, there are still clear risks that could challenge the current narrative around Revolution Medicines, including significant projected operating expenses and the company’s exclusive pipeline focus on RAS-targeted oncology.

Another View on Revolution Medicines' valuation

The analyst narrative suggests Revolution Medicines is 39.2% overvalued at $186.16 versus a fair value of $133.70, but the Simply Wall St DCF model points the other way, with an estimated future cash flow value of $697.80, implying the stock trades at a steep discount instead. That kind of gap raises the question: which set of assumptions do you trust more, the market or the DCF model?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Revolution Medicines for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such different views on Revolution Medicines, do you want to rely on one narrative or test the assumptions yourself? Take a closer look at the underlying data, then weigh up the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Revolution Medicines?

If you stop at Revolution Medicines, you risk missing other opportunities. Put a few minutes into broadening your watchlist so your next decision is properly informed.

• Spot potential mispricings early and scan screener containing 20 high quality undiscovered gems that combine strong fundamentals with less crowd attention.
• Strengthen your defensive core and review 82 resilient stocks with low risk scores that aim for resilience when conditions get tougher.
• Build a steadier income stream and assess 8 dividend fortresses offering higher yields with a focus on durability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.